NCT07284654Phase 3Completed

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Study sponsor: Vaxcyte, Inc. · PCVX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-09-17Actual
Enrollment · participants4049Actual
Source updated2026-10-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jan 2027. After: 17 Sep 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 4000 participants (planned). After: 4049 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source